Quick Answer
Travere Therapeutics, Inc. reported Earnings Per Share Diluted of $0.29 (loss) per share for the year ending 2025.
- Travere Therapeutics, Inc. showed an increase of +92.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Travere Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 88.1%.
- Historical annual values: Fiscal year 2025: $0.29 (loss) per share | Fiscal year 2024: $4.08 (loss) per share | Fiscal year 2023: $1.50 (loss) per share | Fiscal year 2022: $4.37 (loss) per share | Fiscal year 2021: $3.01 (loss) per share | Fiscal year 2020: $3.56 (loss) per share | Fiscal year 2019: $3.46 (loss) per share | Fiscal year 2018: $2.54 (loss) per share | Fiscal year 2017: $1.54 (loss) per share | Fiscal year 2016: $1.29 (loss) per share | Fiscal year 2015: $3.17 per share | Fiscal year 2014: $4.43 (loss) per share | Fiscal year 2013: $2.44 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: